← Back to headlines
Wedbush Bullish on Black Diamond Therapeutics (BDTX) After Silevertinib Program Progress
Wedbush maintains a bullish outlook on Black Diamond Therapeutics (BDTX) following advancements in its Silevertinib program.
25 Mar, 19:31 — 25 Mar, 19:31
Sources
Showing 1 of 1 sources
